This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ThousandOaks-based Amgen said Wednesday afternoon that it is cutting 380 jobs from the firm, as part of a corporate restructuring. The firm said it is cutting 226 people in its ThousandOaks headquarters. READ MORE>>.
ThousandOaks-based biotech Amgen is acquiring Iceland-based deCODE Genetics , in a deal worth $415M in cash, the two companies announced this morning. deCODE Genetics is a provider of human genetic research which was founded in 1996.
ThousandOaks-based Teledyne Technologies said last week that it has acquired Photon Machines , a developer of laser-based, laboratory instrumentation. Its corporate headquarters and research labs are in ThousandOaks. Financial terms of the buy were not disclosed. Photon Machines was based in Bozeman, Montana.
ThousandOaks-based Teledyne Technologies said this morning that it has acquired a majority interest in Solvang-based Nova Sensors. Nova Research designs camera electronics, infrared camera systems, and integrated circuits. Financial terms of the deal were not disclosed. READ MORE>>.
ThousandOaks-based Ceres , a developer of energy crops for the biofuels energy, has landed $4,989,144 in a grant from the Department of Energy, as part of a $151M effort to fund energy breakthroughs.
ThousandOaks-based biotech giant Amgen said Friday that it has named R. Williams is president of Gladstone Institutes, a nonprofit biomedical research enterprise, and is also a Professor of Medicine at the University of California, San Francisco. Sander Williams, M.D., to its board of directors.
ThousandOaks-based Teledyne Technologies has acquired Carlsbad-based Oceanscience Group Ltd. , teledyne oceanscience merger acquisition ocean research vehicle unmanned' a developer of unmanned marine vehicles and sensor platforms. Financial terms of the buy were not disclosed. READ MORE>>.
ThousandOaks-based Teledyne Technologies said Friday that it has scored a commercial laboratory services contract, via its subsidiary, Teledyne Brown Engineering, with The Dow Chemical Company. Financial impact of the win was not disclosed. Freeport, Texas, and Spring House, Pa. Freeport, Texas, and Spring House, Pa. READ MORE>>.
ThousandOaks-based ImmunGene , a startup biotech company developing antibody-based, protein therapeutics for treating cancer, said today that it has raised $9M in a Series A funding, to advance its early stage development products. According to the company, the funding came from Ally Bridge Group. The startup is led by Sanjay D.
Thousandoaks-based biotech giant Amgen said Tuesday that the firm is taking part in a preclinical test on the final, NASA Space Shuttle mission scheduled to launch Friday.
ThousandOaks-based Teledyne Technologies announced this moring that the firm's subsidiary, Teledyne Instruments, inc., Ocean Design is a Florida-based manufacturer of undersea, electrical and fiber-optic interconnect systems used in oil and gas production, oceanographic research, and military applications.
ThousandOaks-based seed biotechnology developer Ceres reports this morning that it has been awarded a U.S. 8,710,201, covers use of a gene in areas of research, product development, and seed production. patent on a genetic sequence derived from corn. The company said the patent, U.S.
The organization said that ThousandOaks-based Angel Sharks , a team of students, educators and entrepreneurs with expertise in artificial intelligence research and development; and San Diego-based Boardformula , a team from an engineering consultancy for research and development in the surf industry, both will move on in the competition.
ThousandOaks-based agricultural biotechnology developer Ceres , which is developing biotech-driven sorghum seeds for use in reneable fuel and electricity production, said it has expanded its product develoment activities in Meixco.
ThousandOaks-based Ceres , a developer of biofuel crop technology, and Novozymes , a developer of enzymes, said today that the two have entered into a research collaboration around cellulosic biofuel production.
Atara Biotherapeutics , the biopharmaceuticals firm which has its manufacturing and research efforts based in ThousandOaks, said on Thursday that its current President and CEO, Isaac Ciechanover, M.D., The company is based in South San Francisco, but was founded in ThousandOaks and has a large facility in the city.
ThousandOaks-based biotech Amgen has linked with a university in Shanghai, China, to open up a new R&D center. According to Amgen, it has entered into a strategic partnership with ShanghaiTech University , to open up a research and development center at the university''s campus. READ MORE>>.
ThousandOaks-based Amgen , along with partners Novartis and the Banner Alzheimer's Institute , said late last week that they are discontinuing a clinical research program, which had focused on Alzheimer's prevention.
ThousandOaks-based Teledyne Technologies announced on Wednesday afternoon that it has acquired a number of scientific imaging brands from Roper Technologies , in a deal worth $225M in cash. According to Teledyne, the businesses include Princeton Instruments, Photometrics and Lumenera, as well as other brands.
ThousandOaks-based biotechnology giant Amgen has entered into a new collaboration effort, with precision medicine developer Syapse. According to the two companies, they will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.
ThousandOaks-based Capsida Biotherapeutics, a new biotechnology company focused on using adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases, has uncloaked from stealth mode, saying it has raised $140M in total capital.
ThousandOaks-based Amgen announced Thursday that it has entered into a strategic collaboration with BeiGene the expand its oncology research efforts in China. According to Amgen, it paid $2.8 billion in cash to acquire a 20.5 percent stake in BeiGene.
ThousandOaks-based Amgen said on Thursday afternoon that it has taken a 20.5 percent stake in BeiGene , a research-based, oncology-focused biotechnology company in China. According to Amgen, it paid approximately $2.7 billion in cash for the stake in BeiGene, which it says it will use to expand its oncology presence in China.
ThousandOaks-based biotech giant Amgen is the a new investor in a round for Alector , a developer of immuno-modulatory therapies for Alzheimer's disease and other neurogenerative disorders, which announced a $29.5M funding today. READ MORE>>.
ThousandOaks-based Teledyne Technologies has garnered an $18.8M, contract from DARPA, the Defense Advanced Research Project Agency, the firm reported last week. The firm said the contract covers work through 2014, with an initial phase valued at $8.3M over a 24-month period.
ThousandOaks-based biotech giant Amgen said this morning that it has tied with Piper Jordan , a health and benefit consulting firm, to launch a new disease management program for people living with migraine.
ThousandOaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M The company said its technology is based on research from the labs of Professor John Williams at City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University. READ MORE>>.
• Jack Gilbert , once the chief executive officer of a large Los Angeles-based corporation, later founded ThousandOaks Land Development and played a major role in the development of ThousandOaks area, leading that city’s emergence as a major business and corporate center.
And on the West coast, Palo Alto, CA-based Bioz started up with $3 million in seed cash from 5AM Ventures to help develop software meant to help speed up life sciences research. And in other Amgen news, the ThousandOaks, CA, company filed for FDA approval of osteoporosis drug romosuzumab.
So, very early on was our project-Voxel Research, how our name got created and mashed up to Voxearch. The concept of the incubator is we''re raising a fund here locally and ten percent is local the other 90 percent on AngelList, and we''ll be locating here in the town of ThousandOaks. We have city and school support for that.
—Amgen (NASDAQ: AMGN ), of ThousandOaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen. Shares of Catabasis surged 43 percent.
—Amgen (NASDAQ: AMGN ) of ThousandOaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. .
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content